The diagnosis and treatment of gastrointestinal (GI) disorders
has been greatly improved by the SmartPill, an ingestible
diagnostic sensing capsule that travels every inch of the
30-foot-long human GI tract while making and recording key
measurements.
After patients swallow the SmartPill, which is slightly larger
than a multivitamin, they go about their normal routines as the
device travels through their digestive system, continuously
relaying information on temperature, pH, pressure and transit time
to a compact monitor worn on the belt.
After one or two days, the capsule is excreted, patients return
the monitor to their physician and specialized software generates a
detailed report on the GI system’s functioning.
“It’s a very elegant solution,” says David L.
Barthel, president and CEO of The SmartPill Corp., the medical
device company on the Buffalo Niagara Medical Campus that developed
the capsule. “Standard methods of examining the GI tract have
such negative implications that they put people off. Patients
haven’t wanted to go through the procedures, so they often
suffer in silence.”
One such condition that is believed to affect three million
Americans severely enough to require hospitalization is called
gastroparesis—the inability of the stomach to empty. Common
causes for the condition include diabetes and obesity; however, in
up to 40 percent of the cases, the etiology remains unknown.
Michael D. Sitrin, MD, professor of medicine at UB and chief of
the division of gastroenterology, hepatology and nutrition,
co-directed the seven-site clinical trial of the SmartPill.
“What we know about the motility of the GI tract has been
coming from situations where it is very difficult to do research.
You have patients sitting there for a short period of time with
tubes down them—a very artificial situation.
“This new method gives you a chance to get some of these
measurements in people who are in a much more natural situation. It
really represents a new step forward.”
In 2006, the SmartPill received approval by the Food and Drug
Administration. Three years later, it was highlighted in a Forbes
magazine story on cutting-edge life-saving technologies.